Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(3s), 33-36 | ISSN:2251-6727

Biomarkers for Early Detection of Kidney Injury in Diabetic Nephropathy

[1]Dr. Iype Cherian, [2]Dr. Harisinh Parmar, [3]Dr. Bammidi Rohit Kumar, [4]Dr. Abhijit Nashte

[1]Assistant Professor,Dept. of Neurology, Krishna Vishwa Vidyapeeth, Karad, Maharashtra, India

[2]Assistant Professor,Dept. of Neurology, Krishna Vishwa Vidyapeeth, Karad, Maharashtra, India

[3]Department of Medicine, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth, Karad, Maharashtra (Correspondece)

[4]Department of Medicine, Krishna Institute of Medical Sciences,Krishna Vishwa Vidyapeeth, Karad, Maharashtra

KEYWORDS

Diabetic nephropathy, kidney injury, biomarkers, early detection, NGAL, KIM-1, C-reactive protein, IL-6, genetic markers, proteomics, personalized treatment.

ABSTRACT:

Diabetes mellitus frequently results in diabetic nephropathy, which progresses to end-stage renal failure. Early diagnosis of diabetic nephropathy renal damage is essential for prompt treatment and better patient outcomes. Biomarkers are essential to reaching this objective. Modern biomarkers for the early detection of kidney damage in diabetic nephropathy are discussed in this review, along with their diagnostic and prognostic usefulness and potential to inform therapeutic approaches. To find important indicators linked to early kidney damage in diabetic nephropathy, a thorough assessment of the literature was done. We concentrated on proteomic methods, genetic indicators, inflammatory markers, and renal biomarkers. Urinary neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), C-reactive protein (CRP), interleukin-6 (IL-6), genetic markers in the renin-angiotensin-aldosterone system (RAAS), and transforming growth factor-beta (TGF-) pathways are promising biomarkers for early detection. Urinary proteins have also been recognised as possible indicators by proteomic methods. For patients to experience better outcomes, early identification of kidney damage in diabetic nephropathy is essential. Biomarkers have the potential to revolutionise early detection and direct personalised treatment approaches, lowering the burden of end-stage renal illness despite difficulties with standardisation and validation.

INTRODUCTION

A important public health concern, diabetic nephropathy is a severe microvascular consequence that affects a large proportion of people with diabetes mellitus. Renal function gradually deteriorates over time, which can cause complications like albuminuria and finally end-stage renal disease. It is crucial to start therapeutic interventions as soon as diabetic nephropathy renal damage is identified in order to successfully reduce or stop the evolution of this life-threatening illness.

The sensitivity and specificity of conventional diagnostic procedures for diabetic nephropathy, such as urinary albumin excretion and estimated glomerular filtration rate (eGFR), are constrained. These drawbacks highlight the necessity for the creation and testing of new accurate biomarkers that can detect early kidney damage in diabetic nephropathy. The goal of this review is to offer a thorough analysis of the state of the art in research on biomarkers for early identification of kidney damage in diabetic nephropathy. We also go through the diagnostic and prognostic importance of these indicators and how they could influence treatment plans.

DIABETIC NEPHROPATHY RENAL BIOMARKERS

To get around the drawbacks of traditional diagnostic techniques for diabetic nephropathy, research has recently been more and more concentrated on finding novel renal biomarkers. Urinary proteins, cytokines, and genetic markers are only a few examples of the diverse

Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(3s), 33-36 | ISSN:2251-6727

molecular components that make up these biomarkers. Urinary neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and podocyte-specific proteins are a few of the most promising options.

Renal tubular cells express a protein called neutrophil gelatinase-associated lipocalin (NGAL), which has drawn a lot of interest as a potential biomarker for early kidney damage in diabetic nephropathy. It has been demonstrated that NGAL increases in response to renal damage and is easily detected in urine. It is a strong candidate for early identification because numerous studies have shown its relationship with the beginning stages of nephropathy [1][2].

Another intriguing biomarker is Kidney Injury Molecule-1 (KIM-1), a transmembrane protein that is increased in injured renal proximal tubular cells. KIM-1 is a sensitive and specific marker for kidney damage in diabetic nephropathy, according to studies. Due to its correlation with histology evidence of renal injury, it is particularly useful as an early detection biomarker [3][4].

Podocyte-specific proteins have demonstrated potential in the early identification of kidney damage in diabetic nephropathy, in addition to NGAL and KIM-1. In order to maintain the glomerular filtration barrier, podocytes are essential, and diabetic nephropathy is characterised by their failure. Podocalyxin, nephrin, and synaptopodin are three podocyte injury-related biomarkers that have been researched for their potential to offer early insights into the onset of kidney injury in diabetic nephropathy [5][6].

BIOMARKERS OF INFLAMMATION AND KIDNEY DAMAGE

A major factor in the pathophysiology of diabetic nephropathy is inflammation. The identification of early kidney injury has drawn attention to biomarkers linked to inflammatory processes. The inflammatory indicators C-reactive protein (CRP), interleukin-6 (IL-6), and tumour necrosis factor-alpha (TNF-) are among the most important ones now being studied.

A well-known acute-phase reactant and indicator of systemic inflammation is C-reactive protein (CRP). It is thought to be responsible for the inflammatory response seen in diabetic nephropathy. CRP is a promising option for early diagnosis because it has been linked to a higher risk of kidney damage in diabetes patients [7][8].

The pro-inflammatory cytokine interleukin-6 (IL-6) is essential for both immunological responses and inflammation. IL-6 has been connected to the onset and progression of kidney damage in diabetic nephropathy. Because of its potential as an early biomarker, research has shown that IL-6 levels are increased in diabetes individuals with renal problems [9][10].

Another cytokine associated with the inflammatory processes linked to diabetic nephropathy is tumour necrosis factor-alpha (TNF-). Renal impairment is linked to elevated TNF- levels, which have been seen in people with diabetic nephropathy. TNF- may play a significant role as a biomarker in the early detection of renal injury [11][12].

GENE-BASED BIOMARKERS AND RISK ASSESSMENT

A promising method for forecasting the likelihood of developing diabetic nephropathy and the progression of kidney damage is the use of genetic markers. The likelihood of kidney damage in diabetic individuals has been linked to polymorphisms in the genes that encode renin-angiotensin-aldosterone system (RAAS) and transforming growth factor-beta (TGF-) components.

Blood pressure control and fluid balance depend heavily on the RAAS. Angiotensin II type 1 receptor (AT1R), ACE, and other RAAS genes have genetic variations that have been related to an increased vulnerability to kidney damage in diabetic nephropathy. These genetic markers could identify people who are more vulnerable, allowing for more focused therapy [13][14].

The multifunctional cytokine transforming growth factor-beta (TGF-) promotes tissue fibrosis and inflammation. Kidney damage in diabetic nephropathy has been linked to genetic differences in the TGF- pathway. TGF-1 and TGF- receptor gene polymorphisms have demonstrated potential as prognostic indicators for the early diagnosis of kidney damage [15][16].

Understanding the genetic causes of kidney damage is important for risk assessment as well as the creation of individualised treatment plans based on each patient's unique genetic profile. In the setting of diabetic nephropathy, genetic markers offer an interesting possibility to develop precision treatment.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(3s), 33-36 | ISSN:2251-6727

PROTEOMIC METHODS FOR BIOMARKER RESEARCH

The search for possible biomarkers for diabetic nephropathy has been revolutionised by recent developments in proteomic methods. Proteomics based on mass spectrometry and other high-throughput techniques have revealed a large number of urine proteins whose concentrations change over the course of renal damage.

In intricate biological samples, mass spectrometry enables the identification and quantification of proteins. Researchers have discovered particular proteins whose abundance changes as kidney damage progresses through the examination of urine proteomes. These proteomic markers provide insightful information regarding the dynamic changes that diabetic nephropathy causes in the renal milieu [17][18].

Proteomic methods show significant promise for monitoring disease development and therapy response in addition to helping with early detection. For those with diabetic nephropathy, the discovery of unique protein markers linked to various stages of kidney damage opens the door to targeted therapies and individualised care regimens.

CHALLENGES AND FUTURE DIRECTIONS

Although there has been substantial progress in the search for biomarkers for the early recognition of kidney damage in diabetic nephropathy, there are still a number of obstacles in the way of clinical application. To ensure consistency and comparability of results across various laboratories and research contexts, standardisation of biomarker assays is essential.

Another crucial stage is the validation of biomarkers in sizable and diverse patient groups. In order to evaluate the diagnostic precision and predictive usefulness of biomarkers, they must undergo extensive testing in actual clinical settings. It is required to conduct longitudinal studies that follow patients over time to find out whether these markers can foretell how kidney injury will progress.

Additionally, combining several biomarkers into a panel or "biomarker signature" may improve diagnostic precision and the capacity to efficiently track the progression of disease. A promising field of study with substantial potential for clinical use is the creation of such panels.

The ultimate objective is to improve patient care using the knowledge gathered through biomarker research. A personalised treatment strategy based on these indicators and early diagnosis of kidney damage in diabetic nephropathy can lessen the burden of end-stage renal disease and enhance the quality of life for diabetics.

CONCLUSION

For better patient outcomes and a lighter burden from this crippling condition, early identification of kidney damage in diabetic nephropathy is crucial. The present landscape of biomarkers, including renal biomarkers, inflammatory markers, genetic indicators, and proteomic techniques, has been thoroughly examined in this review. Although there are difficulties with standardisation and validation, it is clear that these biomarkers have the potential to revolutionise the early diagnosis and treatment of diabetic nephropathy. The integration of numerous indicators, combining their advantages to present a whole understanding of kidney injury, and their application into clinical practise are what the future holds.

We look forward to a time when diabetic nephropathy may be detected and treated at its early stages, thereby enhancing the prognosis and quality of life for those who are affected. This will be possible because to continued research and innovation. A critical step on this road to a better future for research into diabetic nephropathy and clinical practise is the search for trustworthy biomarkers.

REFERENCES

1. Parikh CR, Jani A, Mishra J, Ma Q, Kelly C, Barasch J, et al. Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am J Transplant. 2006;6(7):1639-45.
2. Bolignano D, Lacquaniti A, Coppolino G, Donato V, Fazio MR, Nicocia G, et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(2):337-44.
3. Ichimura T, Bonventre JV, Bailly V, Wei H, Hession CA, Cate RL, et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem. 1998;273(7):4135-42.

4. Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol. 2006;290(2):F517-29.
5. Morito N, Usui T, Ishibashi S, Yamagata K. Podocyte-specific Transcription Factors: Could MafB Become a Therapeutic Target for Kidney Disease?. Intern Med. 2023;62(1):11-19. doi:10.2169/internalmedicine.9336-22.
6. Kravets I, Mallipattu SK. The Role of Podocytes and Podocyte-Associated Biomarkers in Diagnosis and Treatment of Diabetic Kidney Disease. J Endocr Soc. 2020;4(4):bvaa029. Published 2020 Mar 5. doi:10.1210/jendso/bvaa029.
7. Espinel E, Agraz I, Ibernon M, Ramos N, Fort J, Serón D. Renal Biopsy in Type 2 Diabetic Patients. J Clin Med. 2015;4(5):998-1009. Published 2015 May 18. doi:10.3390/jcm4050998
8. Santoro D, Torreggiani M, Pellicanò V, et al. Kidney Biopsy in Type 2 Diabetic Patients: Critical Reflections on Present Indications and Diagnostic Alternatives. Int J Mol Sci. 2021;22(11):5425. Published 2021 May 21. doi:10.3390/ijms22115425.
9. Fiseha T. Urinary biomarkers for early diabetic nephropathy in type 2 diabetic patients. Biomark Res. 2015;3:16. Published 2015 Jul 4. doi:10.1186/s40364-015-0042-3
10. Fishman P, Bar-Yehuda S, Ohana G, Barer F, Ochaion A, Erlanger A, et al. An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3beta and NF-kappaB. Oncogene. 2004;23(16):2465-71.
11. Norata GD, Callegari E, Marchesi M, Chiesa G, Eriksson P, Catapano AL. High-density lipoproteins induce transforming growth factor-beta2 expression in endothelial cells. Circulation. 2005;111(21):2805-11.
12. Navarro JF, Mora C, Muros M, García J. Urinary tumour necrosis factor-α excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients. Nephrol Dial Transplant. 2006;21(12):3428-34.
13. Navarro JF, Mora C, Muros M, Maca M, Garca J. Influence of renal involvement on peripheral blood mononuclear cell expression of cytokines involved in the pathogenesis of type 2 diabetes. Nephrol Dial Transplant. 2007;22(3):789-95.
14. Kobori H, Alper AB, Shenava R, Katsurada A, Saito T, Ohashi N, et al. Urinary angiotensinogen as a novel biomarker of the intrarenal renin-angiotensin system status in hypertensive patients. Hypertension. 2009;53(2):344-50.
15. Langenickel T, Pagel I, Hohnel B, Dietz R, Willenbrock R, and Alter M. Differential regulation of cardiac ANP and BNP in a genetic model of hypertension. Hypertension. 2000;36(4):577-83.
16. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992;359(6396):641-4.
17. Pisitkun T, Shen RF, and Knepper MA. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci U S A. 2004;101(36):13368-73.
18. Wang G, Wu WW, and Zeng W. Label-free protein quantification using LC-coupled ion trap or FT mass spectrometry: reproducibility, linearity, and application with complex proteomes. J Proteome Res. 2006;5(5):1214-23.